Hepatitis C and liver transplantation;Hépatite C et transplantation hépatique

Gastroenterologie Clinique et Biologique

Volumn 26, Issue SPEC. 2, 2002, Pages

  Durand, François ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; RIBAVIRIN;

CHRONIC KIDNEY FAILURE; COMORBIDITY; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE SEVERITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; ORGAN DONOR; POSTOPERATIVE COMPLICATION; RECURRENT DISEASE; RISK FACTOR; TREATMENT INDICATION;

AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; ENZYME TESTS; FOLLOW-UP STUDIES; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSION; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RIBAVIRIN; RISK FACTORS; RNA, VIRAL; TIME FACTORS; TISSUE DONORS; TRANSAMINASES;

EID: 17044443701     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (73)

1. Treatment of patients with chronic hepatitis C and cirrhosis
2. Primary liver resection and salvage transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: An outcome oriented decision analysis
3. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
4. Predictors of patient and graft survival following liver transplantation for hepatitis C
5. A 10-year experience of liver transplantation for hepatitis C: Analysis of factors determining outcome in over 500 patients
6. Detection of hepatitis C virus replication in peripheral blood mononuclear cells after orthotopic liver transplantation
7. Detection of hepatitis C virus RNA in CD19 peripheral blood mononuclear cells of chronically infected patients
8. Hepatitis C virus in peripheral blood mononuclear cells from a chronically infected patient receiving liver graft from infected donor
9. Reinfection of liver graft by hepatitis C virus after transplantation
10. Recurrent and acquired hepatitic viral infection in liver transplant recipients
11. Serial quantitative determination of hepatitis C virus RNA levels after liver transplantation
12. Frequency and severity of HCV infection following orthotopic liver transplantation: Effects of donor and recipient serology HCV using a second generation ELISA test
13. Antibody response to hepatitis C virus infection after liver transplantation
14. Serologic responses to hepatitis C virus in solid organ transplant recipients
15. Persistent hepatitis C virus infection after liver transpantation: Clinical and virological features
16. Hepatitis C virus reinfection in allografts after liver transplantation
17. Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions
18. A longitudinal study of hepatitis C virus replication following liver transplantation
19. Quantitation of hepatitis C virus RNA in liver transplant recipients
20. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation
21. Hepatitis C virus related fibrosing cholestatic hepatitis after renal transplantation
22. Long term outcome of hepatitis C infection after liver transplantation
23. HCV-related fibrosis progression following transplantation: Increase in recent years
24. Natural history of liver fibrosis progression in patients with chronic hepatitis C
25. Pretransplantation virological markers of hepatitis C virus genotype and viremia level are not helpful in predicting individual outcome after orthotopic liver transplantation
26. Severity of liver disease in liver transplant recipients with hepatitis C virus infection: Relationships to genotypes and level and viremia
27. Serum hepatitis C RNA titers after liver transplantation are not correlated with immunosuppression or hepatitis
28. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate
29. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation
30. Influence of genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation
31. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation
32. Hepatitis C virus genotypes in liver transplant recipients
33. Histological and clinical outcome after liver transplantation for hepatitis C
34. Timing and seventy of initial hepatitis C recurrence as predictors of long-term liver allograft injury
35. Influence of immunogenetic background on the outcome of recurrent hepatitis C after liver transplantation
36. Pretransplantation hepatitis C virus quasispecies may be predictive of outcome after liver transplantation
37. Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation
38. Hepatitis G virus coinfection does not alter the course of recurrent hepatitis C virus infection in liver transplantation recipients
39. Comparison tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation
40. Hepatitis C viral infection in liver transplantation
41. Recurrent hepatitis C virus infection in liver transplant recipients receiving tacrolimus: Association with rejection and increased immunosuppression after transplantation
42. Early development of chronic active hepatitis in recurrent hepoatitis C virus infection after liver transplantation: Association with treatment rejection
43. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation
44. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation
45. Association of multispecific CD4+ response to hepatitis C and severity of recurrence after liver transplantation
46. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C
47. A 10-year experience of liver transplantation for hepatitis C: Analysis of factors determining outcome in over 500 patients
48. Liver transplantation for hepatitis C virus-related cirrhosis
49. The course of hepatitis C virus infection after liver transplantation
50. Orthotopic liver transplantation for hepatitis C. Outcome, effect of immunosuppression, and causes of retransplantation during a 8-year single-center experience
51. Retransplantation for recurrent hepatitis C
52. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol or cholestatic liver disease
53. Postransplant diabetes mellitus in liver transplant recipients: Risk factors, temporal relationships with hepatitis C virus allograft hepatitis and impact on mortality
54. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation
55. Increased risk of posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C
56. Renal disease in hepatitis C positive liver transplant recipents
57. Outcome of hepatitis C virus-associated membranoproliferative glomerulonephritis after liver transplantation
58. Long-term outcome of patients transplanted with liver from hepatitis C-positive donors
59. Outcome of liver transplantation in hepatitis C virus infected patients who received hepatitis C virus infected grafts
60. Solid organ transplantation in patients with HIV infection
61. Interferon-α therapy for hepatitis C virus infection after liver transplantation
62. An open trial of interferon alpha recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection
63. Interferon alpha therapy for hepatitis C virus recurrence after liver transplantation: Long-term response with maintenance therapy
64. A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation
65. Pilot study of the combination of interferon alfa and ribavirin as therapy for recurrent hepatitis C after liver transplantation
66. Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin
67. Interferon-a and ribavirin for the treatment of recurrent hepatitis C after liver transplantation
68. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin
69. Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients
70. Daily interferon therapy for hepatitis C virus infection in liver transplant recipients
71. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis recurrence after liver transplantation
72. Interferon-α for prophylaxis of recurrent viral hepatitis C in liver transplant recipients
73. The efficacy of prohylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation